
Enovis Corp (ENOV) Stock Forecast & Price Target
Enovis Corp (ENOV) Analyst Ratings
Bulls say
Enovis is a growing company in the medical technology industry with a diversified portfolio of products catering to different segments of the market. With a focus on consistently delivering organic revenue growth and launching new products with meaningful clinical impact, the company has a strong potential for future growth. Additionally, the company's solid financial position and improving margins make it an attractive investment opportunity.
Bears say
Enovis is currently facing significant challenges such as slower-than-expected top-line growth, competitive pressure in its key segment of Reconstructive products, and a lack of new product innovation. This has led to multiple contraction, and the company is facing additional headwinds from tariff impacts and difficulty with M&A integration. It is currently trading at a discount compared to its peers due to lower growth projections, but the potential for upside exists if it can improve margins, successfully integrate M&A, and overcome tariff impacts. In the base case scenario, revenue is expected to be in the range of $2.31B - $2.37B, with a focus on growth in its Prevention & Recovery segment and lower growth in its Recon segment. Our analysis suggests that the stock is currently trading at a discount, with potential for multiple expansion in the future.
This aggregate rating is based on analysts' research of Enovis Corp and is not a guaranteed prediction by Public.com or investment advice.
Enovis Corp (ENOV) Analyst Forecast & Price Prediction
Start investing in Enovis Corp (ENOV)
Order type
Buy in
Order amount
Est. shares
0 shares